Study to evaluate the pharmacokinetics, safety and tolerability of Secukinumab in patients with GCA or PMR
CAIN457E22101
Phase 1 other active
Quick answer
Study to evaluate the pharmacokinetics, safety and tolerability of Secukinumab in patients with GCA or PMR for Polymyalgia rheumatica (PMR), Giant cell arteritis (GCA) is a Phase 1 program (other) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Polymyalgia rheumatica (PMR), Giant cell arteritis (GCA)
- Phase
- Phase 1
- Modality
- other
- Status
- active